Another study by Whittington et al. utilized an approach to treat autoimmune diseases which targets only the pathogenic CD4+ T cells responsible for the autoimmune disease pathology by incorporating the HLA-DRB1×01:01 (DR1) and a model autoantigen as part of the CAR molecular structure. Here, DR1 is linked to autoimmune disease.